Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis

Research output: Contribution to journalArticle

Nancy L. Monson, Petra Cravens, Rehana Hussain, Christopher T. Harp, Matthew Cummings, Maria de Pilar Martin, Li Hong Ben, Julie Do, Jeri Anne Lyons, Amy Lovette-Racke, Anne H. Cross, Michael K. Racke, Olaf Stüve, Mark Shlomchik, Todd N. Eagar

Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.

Original languageEnglish (US)
Article numbere17103
JournalPloS one
Volume6
Issue number2
DOIs
StatePublished - Feb 28 2011

PMID: 21359213

PMCID: PMC3040191

Altmetrics

Cite this

Standard

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. / Monson, Nancy L.; Cravens, Petra; Hussain, Rehana; Harp, Christopher T.; Cummings, Matthew; Martin, Maria de Pilar; Ben, Li Hong; Do, Julie; Lyons, Jeri Anne; Lovette-Racke, Amy; Cross, Anne H.; Racke, Michael K.; Stüve, Olaf; Shlomchik, Mark; Eagar, Todd N.

In: PloS one, Vol. 6, No. 2, e17103, 28.02.2011.

Research output: Contribution to journalArticle

Harvard

Monson, NL, Cravens, P, Hussain, R, Harp, CT, Cummings, M, Martin, MDP, Ben, LH, Do, J, Lyons, JA, Lovette-Racke, A, Cross, AH, Racke, MK, Stüve, O, Shlomchik, M & Eagar, TN 2011, 'Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis' PloS one, vol. 6, no. 2, e17103. https://doi.org/10.1371/journal.pone.0017103

APA

Monson, N. L., Cravens, P., Hussain, R., Harp, C. T., Cummings, M., Martin, M. D. P., ... Eagar, T. N. (2011). Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PloS one, 6(2), [e17103]. https://doi.org/10.1371/journal.pone.0017103

Vancouver

Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, Martin MDP et al. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PloS one. 2011 Feb 28;6(2). e17103. https://doi.org/10.1371/journal.pone.0017103

Author

Monson, Nancy L. ; Cravens, Petra ; Hussain, Rehana ; Harp, Christopher T. ; Cummings, Matthew ; Martin, Maria de Pilar ; Ben, Li Hong ; Do, Julie ; Lyons, Jeri Anne ; Lovette-Racke, Amy ; Cross, Anne H. ; Racke, Michael K. ; Stüve, Olaf ; Shlomchik, Mark ; Eagar, Todd N. / Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. In: PloS one. 2011 ; Vol. 6, No. 2.

BibTeX

@article{bdd4a14edc8e4ceb93d4abd66eb70c76,
title = "Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis",
abstract = "Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.",
author = "Monson, {Nancy L.} and Petra Cravens and Rehana Hussain and Harp, {Christopher T.} and Matthew Cummings and Martin, {Maria de Pilar} and Ben, {Li Hong} and Julie Do and Lyons, {Jeri Anne} and Amy Lovette-Racke and Cross, {Anne H.} and Racke, {Michael K.} and Olaf St{\"u}ve and Mark Shlomchik and Eagar, {Todd N.}",
year = "2011",
month = "2",
day = "28",
doi = "10.1371/journal.pone.0017103",
language = "English (US)",
volume = "6",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis

AU - Monson, Nancy L.

AU - Cravens, Petra

AU - Hussain, Rehana

AU - Harp, Christopher T.

AU - Cummings, Matthew

AU - Martin, Maria de Pilar

AU - Ben, Li Hong

AU - Do, Julie

AU - Lyons, Jeri Anne

AU - Lovette-Racke, Amy

AU - Cross, Anne H.

AU - Racke, Michael K.

AU - Stüve, Olaf

AU - Shlomchik, Mark

AU - Eagar, Todd N.

PY - 2011/2/28

Y1 - 2011/2/28

N2 - Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.

AB - Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues.

UR - http://www.scopus.com/inward/record.url?scp=79951907091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951907091&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0017103

DO - 10.1371/journal.pone.0017103

M3 - Article

VL - 6

JO - PLoS ONE

T2 - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 2

M1 - e17103

ER -

ID: 16788793